External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ATA 2022

-
Coming soon
02:45 AM
Duration 10mins Montreal, Canada
Updated ARROW Data: Pralsetinibâ–¼ In Patients With Advanced Or Metastatic RET-altered Thyroid Cancer (TC)
Hu M, Subbiah V, Mansfield A, Taylor M, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Garralda E, Adkins D, Godbert Y, Ahn M-J, Cassier P, Cho B-C, Lin C-C, Barata T, Zalutskaya A, Scalori, Brose M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar